GENE ONLINE|News &
Opinion
Blog

2021-09-14|

MD Anderson to Develop Microbiome Cancer Therapeutics with CRISPR Gene-Editing

by Tyler Chen
Share To

Immunotherapy uses checkpoint inhibitors to block the checkpoint protein on immune cells, bolstering the immune system’s ability to target cancerous cells more effectively. The therapy brings huge benefits in treating cancer patients but sometimes comes with serious side effects.

 

Gut Microbes Linked to Checkpoint Inhibitor Toxicity

The University of Texas MD Anderson Cancer Center released a study in July identifying specific gut microbes that are associated with the toxicity from combining CTLA-4 and PD-1 targeting checkpoint inhibitors in melanoma patients.

The study, published in Nature Medicine, suggested that combining checkpoint inhibitors with either IL-1R inhibition or edited gut microbiota are two potential strategies to deal with toxicity, creating a positive outlook for microbiome therapeutics in cancer treatment.

 

Developing Microbiome Therapeutics with CRISPR

On September 13, MD Anderson Cancer Center teamed up with Danish biotech SNIPR Biome. They will use CRISPR to edit the genes of specific gut microbiomes to decrease the immune-related side effects of cancer patients who take combined checkpoint inhibitors.

Accomplishing that goal won’t be easy. A human body can harbor trillions of microbes, and making permanent changes to specific microbiota has proven to be tough going. While scientists look towards CRISPR for breakthroughs, the technology poses challenges; for example, microbes don’t usually survive gene editing, and it’s difficult to develop a specific editing tool for them because gut microbiomes are hard to culture in a lab. 

 

A Need to First Identify Microbiome Profiles

The collaboration comes in 2 parts. First, MD Anderson Cancer Center and SNIPR Biome will work together to identify microbiome profiles. Then, they will use SNIPR Biome’s proprietary CRISPR technology to edit the microbiome. It is said the technology can eliminate the specific microbiota without harming the rest of the microbiome. The resulting microbiome therapeutics are expected to regulate gut microbiota in the human body and decrease high-grade adverse events in cancer patients.

As stated by MD Anderson Cancer Center, the therapy will enter preclinical trials during the collaboration which could lead to a potential clinical trial.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
This One-Time Injection Could Cure AIDS
2022-06-21
Why CRY2 matters: Studying Control of Plants and Human Growth
2022-06-20
R&D
Massive Human CRISPR-Based Genotype-Phenotype Map Is Now Complete
2022-06-13
LATEST
Blueprint Medicines Gathers Up To $1.25 Billion in Loans and Investments for Research and Development
2022-07-01
FDA Halts Sanofi’s $3.7B Multiple Sclerosis Investment
2022-07-01
Takeda Reveals Positive Data on Takhzyro at EAACI
2022-07-01
Bon Natural Life Limited Announces Change to Board Composition
2022-06-30
These Pharma Companies Are Laying Off Employees Due to Restructuring
2022-06-30
US Bio-Entrepreneur Program Launches in the UK
2022-06-30
ReCode Therapeutics’ Secures an Extra $120 Million To Support Its Drug Delivery Platform
2022-06-30
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top